SF3B1 AND MDS-RS: THE BIOLOGICAL PERSPECTIVE

被引：0
|
作者：
Fontenay, M. [1 ,2 ]
机构：
[1] Univ Paris Cite, Inst Cochin, INSERM, Paris, France
[2] Hop Cochin, Assistance Publ Hop Paris, Hematol, Paris, France
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS14
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Low frequencies of SF3B1 mutations indicate SF3B1 inhibitor as a novel moleculartargeted drug for colorectal cancer.
    Yamano, Tomoki
    Nakajima, Hidenori
    Tsuda, Satoshi
    Kubo, Shuji
    Hamanaka, Mie
    Kobayashi, Masayoshi
    Yamagishi, Daisuke
    Kuno, Takashi
    Tsukamoto, Kiyoshi
    Tamamoto, Astuko
    Noda, Masafumi
    Matsubara, Nagahide
    Hoon, Dave S. B.
    Tomita, Naohiro
    CANCER RESEARCH, 2013, 73 (08)
  • [42] Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis
    Xicoy, Blanca
    Pomares, Helena
    Morgades, Mireia
    Germing, Ulrich
    Arnan, Montserrat
    Tormo, Mar
    Palomo, Laura
    Orna, Elisa
    Della Porta, Matteo
    Schulz, Felicitas
    Diaz-Beya, Marina
    Esteban, Ada
    Molero, Antonieta
    Lanino, Luca
    Avendano, Alejandro
    Hernandez, Francisca
    Roldan, Veronica
    Ubezio, Marta
    Pineda, Alberto
    Diez-Campelo, Maria
    Zamora, Lurdes
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [43] Mutant SF3B1 promotes malignancy in PDAC
    Simmler, Patrik
    Ioannidi, Eleonora I.
    Mengis, Tamara
    Marquart, Kim Fabiano
    Asawa, Simran
    Van-Lehmann, Kjong
    Kahles, Andre
    Thomas, Tinu
    Schwerdel, Cornelia
    Aceto, Nicola
    Ratsch, Gunnar
    Stoffel, Markus
    Schwank, Gerald
    ELIFE, 2023, 12
  • [44] SF3B1: hotspot mutazionale nei prolattinomi
    Giovanna Mantovani
    Federica Mangili
    L'Endocrinologo, 2021, 22 (3) : 281 - 282
  • [45] CHARACTERIZATION OF CHARACTERISTIC MORPHOLOGICAL ALTERATIONS IN PATIENTS WITH MDS/CMML AND GENE MUTATIONS OF SPLICING DIFFERENT TO SF3B1
    Marco Ayala, J.
    Senent Peris, M. L.
    Vicente, A., I
    Saumell, S.
    Such, E.
    Blanco, A.
    Diaz, A.
    Luna, I
    De la Puerta, R.
    Sanz, G.
    HAEMATOLOGICA, 2019, 104 : 290 - 290
  • [46] SF3B1 mutations in MDS subgroups and s-AML and their association with cytogenetics and other molecular markers
    Jeromin, S.
    Dicker, F.
    Meggendorfer, M.
    Eder, C.
    Grossmann, V.
    Kohlmann, A.
    Kern, W.
    Haferlach, C.
    Haferlach, T.
    Schnittger, S.
    LEUKEMIA RESEARCH, 2013, 37 : S11 - S11
  • [47] Somatic SF3B1 hotspot mutation in prolactinomas
    Chuzhong Li
    Weiyan Xie
    Jared S. Rosenblum
    Jianyu Zhou
    Jing Guo
    Yazhou Miao
    Yutao Shen
    Hongyun Wang
    Lei Gong
    Mingxuan Li
    Sida Zhao
    Sen Cheng
    Haibo Zhu
    Tao Jiang
    Shiying Ling
    Fei Wang
    Hongwei Zhang
    Mingshan Zhang
    Yanming Qu
    Qi Zhang
    Guilin Li
    Junmei Wang
    Jun Ma
    Zhengping Zhuang
    Yazhuo Zhang
    Nature Communications, 11
  • [48] Significance of SF3B1 Mutations in Myeloid Neoplasms
    Gajzer, David C.
    Yeung, Cecilia C. S.
    CLINICS IN LABORATORY MEDICINE, 2023, 43 (04) : 597 - 606
  • [49] Chronic Lymphocytic Leukemia with SF3B1 Mutation
    Quesada, Victor
    Ramsay, Andrew J.
    Lopez-Otin, Carlos
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26): : 2530 - 2530
  • [50] SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
    Sandra Huber
    Torsten Haferlach
    Manja Meggendorfer
    Stephan Hutter
    Gregor Hoermann
    Constance Baer
    Wolfgang Kern
    Claudia Haferlach
    Leukemia, 2022, 36 : 2894 - 2902
12345